Vytrus Biotech, S.A. (BME:VYT)
Spain · Delayed Price · Currency is EUR 16.85
+0.20 (1.20%)
At close: Aug 27, 2026
Vytrus Biotech Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9.69 | 6.09 | 4.7 | 4.48 | 3.51 | |
Revenue Growth | 59.15% | 29.51% | 4.90% | 27.57% | 57.47% |
Cost of Revenue | 0.86 | 0.59 | 0.35 | 0.35 | 0.26 |
Gross Profit | 8.83 | 5.5 | 4.35 | 4.13 | 3.25 |
Selling, General & Admin | 4.83 | 3.76 | 3.29 | 2.86 | 2.29 |
Other Operating Expenses | -0.14 | -0.08 | -0.07 | -0.03 | -0.02 |
Operating Expenses | 5.67 | 4.51 | 3.94 | 3.52 | 2.84 |
Operating Income | 3.16 | 0.98 | 0.4 | 0.61 | 0.41 |
Interest Expense | -0.08 | -0.12 | -0.15 | -0.2 | -0.12 |
Interest & Investment Income | 0.03 | 0.02 | 0.01 | 0.01 | - |
Currency Exchange Gain (Loss) | -0 | -0 | -0.01 | -0 | -0 |
Other Non Operating Income (Expenses) | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
EBT Excluding Unusual Items | 3.13 | 0.91 | 0.29 | 0.44 | 0.31 |
Asset Writedown | - | - | - | - | -0 |
Other Unusual Items | -0 | -0.01 | 0.02 | 0.01 | 0 |
Pretax Income | 3.13 | 0.9 | 0.31 | 0.45 | 0.31 |
Income Tax Expense | 0.23 | -0.12 | -0.24 | -0.15 | -0.14 |
Net Income | 2.9 | 1.02 | 0.54 | 0.61 | 0.45 |
Net Income to Common | 2.9 | 1.02 | 0.54 | 0.61 | 0.45 |
Net Income Growth | 183.70% | 87.36% | -9.96% | 34.49% | 107.48% |
Shares Outstanding (Basic) | 8 | 8 | 7 | - | 7 |
Shares Outstanding (Diluted) | 8 | 8 | 7 | - | 7 |
Shares Change | -0.10% | 11.71% | - | - | 0.43% |
EPS (Basic) | 0.39 | 0.14 | 0.08 | - | 0.06 |
EPS (Diluted) | 0.39 | 0.14 | 0.08 | - | 0.06 |
EPS Growth | 183.99% | 67.72% | - | - | 106.59% |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 2.89 | 1.74 | 0.76 | 0.61 | 0.23 |
Free Cash Flow Per Share | 0.38 | 0.23 | 0.11 | - | 0.03 |
Gross Margin | 91.10% | 90.28% | 92.46% | 92.14% | 92.60% |
Operating Margin | 32.56% | 16.17% | 8.60% | 13.53% | 11.65% |
Profit Margin | 29.89% | 16.76% | 11.59% | 13.50% | 12.81% |
Free Cash Flow Margin | 29.78% | 28.62% | 16.22% | 13.51% | 6.47% |
EBITDA | 3.39 | 1.18 | 0.6 | 0.75 | 0.99 |
EBITDA Margin | 35.00% | 19.33% | 12.67% | 16.82% | 28.06% |
D&A For EBITDA | 0.24 | 0.19 | 0.19 | 0.15 | 0.58 |
EBIT | 3.16 | 0.98 | 0.4 | 0.61 | 0.41 |
EBIT Margin | 32.56% | 16.17% | 8.60% | 13.53% | 11.65% |
Effective Tax Rate | 7.33% | - | - | - | - |